Dominant Negative TGFβ Receptor II and Truncated TIM3 Enhance the Antitumor Efficacy of CAR-T-Cell Therapy in Prostate Cancer

Researchers attempted to improve the tumor killing capability of prostate-specific membrane antigen-chimeric antigen receptor T (CAR-T) cells by targeting T cell immunoglobulin and mucin domain 3 (TIM3) and transforming growth factor beta (TGFβ) receptor II simultaneously.